Ranch Capital Advisors Inc. boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 37.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 14,888 shares of the company’s stock after purchasing an additional 4,017 shares during the quarter. AbbVie accounts for about 1.2% of Ranch Capital Advisors Inc.’s holdings, making the stock its 28th largest holding. Ranch Capital Advisors Inc.’s holdings in AbbVie were worth $3,238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently bought and sold shares of the company. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie in the fourth quarter worth $28,000. Imprint Wealth LLC boosted its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Westend Capital Management LLC purchased a new position in AbbVie during the fourth quarter worth about $29,000. IFC & Insurance Marketing Inc. purchased a new position in AbbVie during the fourth quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID increased its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. 70.23% of the stock is owned by institutional investors.
AbbVie Trading Up 0.1%
Shares of AbbVie stock opened at $254.53 on Friday. The firm has a market capitalization of $449.70 billion, a PE ratio of 125.38, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30. AbbVie Inc. has a 12 month low of $184.63 and a 12 month high of $261.64. The business’s 50-day moving average price is $229.80 and its 200-day moving average price is $221.94.
AbbVie Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio is 340.89%.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on ABBV shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. BMO Capital Markets upped their price objective on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. HSBC reaffirmed a “buy” rating and issued a $300.00 target price on shares of AbbVie in a research note on Monday, July 6th. Citigroup boosted their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Royal Bank Of Canada raised their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.67.
Check Out Our Latest Stock Report on ABBV
Trending Headlines about AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
- Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
- Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
- Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories
- Five stocks we like better than AbbVie
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
